EVAHEART

EVAHEART (Chongqing) Medical Device Co., Ltd. was established on June 3, 2014. The company is mainly engaged in the research and development, production, and sales of world-class high-end medical devices — the implantable left ventricular assist device EVAHEART (artificial heart). This product is the result of more than 50 years of basic research and over 20 years of joint design and development by prestigious institutions such as Waseda University, Tokyo Women's Medical University, Japan's National Institute of Advanced Industrial Science and Technology, and Japan's Sun Medical Technology Research Institute. By fully introducing the technology and promoting its localization in China, EVAHEART has become the only company in China currently approved for both short-term and long-term treatment indications for artificial heart R&D, manufacturing, and sales.As a pioneering, cross-cultural company dedicated to the R&D, manufacturing, and sales of high-tech and innovative cardiac products, EVAHEART will provide comprehensive device solutions for heart failure, establishing an industry chain cluster integrating "industry-university-research-inspection" at an internationally leading level. This will play a significant role in accelerating the revitalization and development of China’s strategic emerging medical device industry.